Loading...
Market
Will U.S. mpox cases decrease by 50% or more by the end of 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
CDC reports and public health data
Story
FDA Approves Emergent's ACAM2000 Mpox Vaccine, Stock Soars 23%
Aug 30, 2024, 05:50 AM
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Emergent BioSolutions' ACAM2000®, a live smallpox vaccine, to include individuals at high risk for mpox infection. This approval comes amid ongoing mpox outbreaks across Africa and other regions, highlighting a critical public health challenge. Following the FDA's decision, Emergent BioSolutions' stock saw a significant increase, soaring by 23%. The ACAM2000 vaccine, initially developed for smallpox, will now play a crucial role in addressing the public health challenge posed by mpox.
View original story
Similar markets
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,001 to 20,000 • 25%
More than 20,000 • 25%
Less than 500 • 25%
500 to 1,000 • 25%
1,001 to 2,000 • 25%
More than 2,000 • 25%
Democratic Republic of Congo • 25%
Kenya • 25%
Nigeria • 25%
Burundi • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Yes • 50%
No • 50%
